Trial Profile
Plans are being finalized for the next clinical trial, which could be a combination study of MB07133, a cytotoxic agent with sorafenib (Nexavar), a cytostatic agent.
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 12 Nov 2007
Price :
$35
*
At a glance
- Drugs MB 7133 (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Metabasis Therapeutics
- 12 Nov 2007 New trial record.